Protagonist Therapeutics Inc (PTGX):企業の財務・戦略的SWOT分析

◆英語タイトル:Protagonist Therapeutics Inc (PTGX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2510
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Protagonist Therapeutics Inc (PTGX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. The company’s product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and disorders. It operates in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

Protagonist Therapeutics Inc Key Recent Developments

May 24,2018: Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
May 16,2018: Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
May 09,2018: Protagonist Therapeutics Reports First Quarter 2018 Financial Results
Mar 07,2018: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results
Dec 14,2017: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Protagonist Therapeutics Inc – Key Facts 6
Protagonist Therapeutics Inc – Key Employees 7
Protagonist Therapeutics Inc – Key Employee Biographies 8
Protagonist Therapeutics Inc – Major Products and Services 9
Protagonist Therapeutics Inc – History 10
Protagonist Therapeutics Inc – Company Statement 11
Protagonist Therapeutics Inc – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Protagonist Therapeutics Inc – Business Description 15
Protagonist Therapeutics Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Protagonist Therapeutics Inc – Strengths 16
Protagonist Therapeutics Inc – Weaknesses 17
Protagonist Therapeutics Inc – Opportunities 18
Protagonist Therapeutics Inc – Threats 19
Protagonist Therapeutics Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Protagonist Therapeutics Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
May 24, 2018: Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer 30
May 16, 2018: Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors 31
May 09, 2018: Protagonist Therapeutics Reports First Quarter 2018 Financial Results 32
Mar 07, 2018: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results 34
Dec 14, 2017: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors 36
Nov 06, 2017: Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 37
Aug 08, 2017: Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights 39
Jun 08, 2017: Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. “Rusty” Williams, to its Board of Directors 41
May 10, 2017: Protagonist Therapeutics Reports First Quarter 2017 Financial Results 42
Mar 07, 2017: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 43
Section 6 – Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Protagonist Therapeutics Inc, Key Facts 6
Protagonist Therapeutics Inc, Key Employees 7
Protagonist Therapeutics Inc, Key Employee Biographies 8
Protagonist Therapeutics Inc, Major Products and Services 9
Protagonist Therapeutics Inc, History 10
Protagonist Therapeutics Inc, Subsidiaries 13
Protagonist Therapeutics Inc, Key Competitors 20
Protagonist Therapeutics Inc, Ratios based on current share price 21
Protagonist Therapeutics Inc, Annual Ratios 22
Protagonist Therapeutics Inc, Annual Ratios (Cont...1) 23
Protagonist Therapeutics Inc, Interim Ratios 25
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Protagonist Therapeutics Inc, Recent Deals Summary 29
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 47
Efficiency Ratios 47

List of Figures
Protagonist Therapeutics Inc, Performance Chart (2014 - 2017) 24
Protagonist Therapeutics Inc, Ratio Charts 26
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★海外企業調査レポート[Protagonist Therapeutics Inc (PTGX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Life & General Insurance Company SAOC (NLIF):企業の財務・戦略的SWOT分析
    National Life & General Insurance Company SAOC (NLIF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Catholic United Financial:企業の戦略的SWOT分析
    Catholic United Financial - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Medtecs International Corp Ltd (546):企業の財務・戦略的SWOT分析
    Summary Medtecs International Corporation Ltd (Medtecs) is a medical device company that manufactures and distributes work wear apparels and medical device and consumables. The company's products include medical devices, healthcare textile work wear and hospitality textiles, among others. It also pr …
  • Tokyo Seimitsu Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Europa Oil & Gas (Holdings) Plc (EOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Europa Oil & Gas (Holdings) Plc (Europa Oil) is an oil and gas company that offers exploration and development services. The company's services include production and development of conventional and unconventional hydrocarbon assets. It operates its assets in East Midlands basin, Aquitain ba …
  • RSA Insurance Group plc:企業の戦略・SWOT・財務情報
    RSA Insurance Group plc - Strategy, SWOT and Corporate Finance Report Summary RSA Insurance Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Neuwave Medical Inc-医療機器分野:企業M&A・提携分析
    Summary NeuWave Medical Inc (NeuWave), a subsidiary of Ethicon US LLC is a medical device company that develops and commercializes energy-based minimally invasive medical devices. Its flagship product, Certus 140 microwave ablation (coagulation) system, is a minimally invasive soft tissue ablation s …
  • Isuzu Motors Ltd (7202):企業の財務・戦略的SWOT分析
    Isuzu Motors Ltd (7202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Oneok Inc (OKE):企業の財務・戦略的SWOT分析
    Oneok Inc (OKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Texas Instruments Inc.:企業の戦略・SWOT・財務分析
    Texas Instruments Inc. - Strategy, SWOT and Corporate Finance Report Summary Texas Instruments Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hitachi Chemical Co Ltd (4217):企業の財務・戦略的SWOT分析
    Hitachi Chemical Co Ltd (4217) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • BioLineRx Ltd (BLRX):企業の財務・戦略的SWOT分析
    BioLineRx Ltd (BLRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bridgeport Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Bridgeport Energy Ltd (Bridgeport Energy), a subsidiary of New Hope Corporation Limited is an oil and gas company that explores, produces and develops oil and gas. The company acquires and operates oil and gas assets in Australia and internationally. It holds and operates assets located in t …
  • Massachusetts Eye and Ear Infirmary-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Eye and Ear Infirmary (MEE) is a healthcare service provider that offers primary, medical and surgical care services. The hospital offers services through departments such as ophthalmology, otolaryngology and patient care services. Its patient care services include patient educ …
  • Shantui Construction Machinery Co Ltd:企業の戦略・SWOT・財務情報
    Shantui Construction Machinery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shantui Construction Machinery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Walker Greenbank PLC:企業の戦略・SWOT・財務情報
    Walker Greenbank PLC - Strategy, SWOT and Corporate Finance Report Summary Walker Greenbank PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nine Dragons Paper (Holdings) Ltd
    Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Immunomedics Inc (IMMU)-医療機器分野:企業M&A・提携分析
    Summary Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and automimmune disorders. The company’s portfolio of antibody-drug conjugates are aimed to sp …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • Oriola-KD Oyj (OKDBV):企業の財務・戦略的SWOT分析
    Oriola-KD Oyj (OKDBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆